Beneficial Effect of Kidney Bean Resistant Starch on Hyperlipidemia-Induced Acute Pancreatitis and Related Intestinal Barrier Damage in Rats.

Abstract

Accumulating attention has been focused on resistant starch (RS) due to its blood-lipid-lowering activities. However, reports on the potential bioactivities of RS for preventing hyperlipidemia acute pancreatitis (HLAP) are limited. Therefore, in this study, an acute pancreatitis model was set up by feeding a hyperlipidemia diet to rats, and subsequently evaluating the anti-HLAP effect of RS in kidney beans. The results show that the IL-6, IL-1β, and TNF-α of serum in each RS group were decreased by 18.67-50.00%, 7.92-22.89%, and 8.06-34.04%, respectively, compared with the model group (MOD). In addition, the mRNA expression of tight junction protein ZO-1, occludin, and antibacterial peptides CRAMP and DEFB1 of rats in each RS group increased by 26.43-60.07%, 229.98-279.90%, 75.80-111.20%, and 77.86-109.07%, respectively. The height of the villi in the small intestine and the thickness of the muscle layer of rats were also increased, while the depth of the crypt decreased. The present study indicates that RS relieves intestinal inflammation, inhibits oxidative stress, and prevents related intestinal barrier damage. These results support the supplementation of RS as an effective nutritional intervention for HLAP and associated intestinal injury.

• Authors: Zhaohang Zuo, Shuting Liu, Weiqiao Pang, Baoxin Lu, Wei Sun, Naidan Zhang, Xinyu Zhou, Dongjie Zhang, Ying Wang
• Journal: Molecules (Basel, Switzerland) (Molecules) Vol. 27 Issue 9 (Apr 27 2022) ISSN: 1420-3049 [Electronic] Switzerland
• PMID: 35566136 (Publication Type: Journal Article)

Chemical References

• Defb1 protein, rat
• Defensins
• Resistant Starch

Topics

• Acute Disease
• Animals
• Defensins (pharmacology)
• Hyperlipidemias (drug therapy, etiology, metabolism)
• Intestinal Mucosa (metabolism)
• Pancreatitis (drug therapy, etiology)
• Phaseolus
• Rats
• Resistant Starch